by Jay Bitkower | May 14, 2019 | Therapeutics Updates
In a report delivered by Thomas Powles, from Queen Mary University, London, the combination therapy of pembrolizumab (Keytruda) and axitinib (Inlyta) had a superior performance, in a 861-patient trial, to sunitinib (Sutent), the current standard of care therapy given...
